Blueprint Medicines’ (BPMC) Buy Rating Reaffirmed at Needham & Company LLC
Needham & Company LLC reiterated their buy rating on shares of Blueprint Medicines (NASDAQ:BPMC – Free Report) in a research report sent to investors on Monday morning, Benzinga reports. The firm currently has a $97.00 price objective on the biotechnology company’s stock. Other analysts also recently issued reports about the company. Raymond James raised their […]
More Stories
IndyCar Race Caps Summer Events for America’s 250th Birthday
By Travis Gillmore WASHINGTON—More than 100,000 spectators lined the streets to witness history as drivers raced by national monuments on...
Zelenskyy Rejects Calls for Wartime Elections in Ukraine
By Tom Gantert Ukrainian President Volodymyr Zelenskyy said holding elections during the war with Russia would “destroy the country,” in...
DOJ Says Diplomat Discipline Board Can’t Overrule Secretary of State
By Matthew Vadum A Department of Justice (DOJ) body held that an independent board that reviews disciplinary actions against U.S....
Retailers See Mixed Sales as Consumers Tighten, Not Retreat
By Panos Mourdoukoutas This earnings season highlighted differing trends at some of the biggest U.S. retailers. At Target and Ross...
Canada to Start Retaliatory Tariffs on US Goods Beginning Sept. 8
By Jacki Thrapp Canadian Prime Minister Mark Carney announced on Saturday that retaliatory tariffs on U.S. goods will take effect...
Judge Strikes Down Trump Admin Policy Suspending Visa Processing From 75 Countries
By Jacki Thrapp A federal judge struck down a Trump administration policy that suspended the issuance of immigrant visas for...